Aberdeen Group plc Grows Position in Dyne Therapeutics, Inc. $DYN

Aberdeen Group plc boosted its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 53.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 483,963 shares of the company’s stock after buying an additional 169,377 shares during the quarter. Aberdeen Group plc’s holdings in Dyne Therapeutics were worth $4,607,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Graham Capital Management L.P. purchased a new position in Dyne Therapeutics during the first quarter valued at $651,000. Rhumbline Advisers lifted its position in Dyne Therapeutics by 4.2% during the first quarter. Rhumbline Advisers now owns 133,627 shares of the company’s stock valued at $1,398,000 after purchasing an additional 5,383 shares in the last quarter. Voleon Capital Management LP purchased a new position in Dyne Therapeutics during the first quarter valued at $624,000. GAMMA Investing LLC lifted its position in Dyne Therapeutics by 837.5% during the first quarter. GAMMA Investing LLC now owns 2,625 shares of the company’s stock valued at $251,000 after purchasing an additional 2,345 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of Dyne Therapeutics by 8.9% in the first quarter. Swiss National Bank now owns 118,300 shares of the company’s stock valued at $1,237,000 after acquiring an additional 9,700 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Trading Down 0.7%

Shares of DYN stock opened at $16.42 on Friday. Dyne Therapeutics, Inc. has a 12-month low of $6.36 and a 12-month high of $35.77. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The stock’s 50-day moving average price is $13.22 and its 200-day moving average price is $11.38. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of -4.25 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.02. Equities research analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Activity

In other news, CEO John Cox sold 2,640 shares of Dyne Therapeutics stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $13.41, for a total value of $35,402.40. Following the sale, the chief executive officer directly owned 199,539 shares of the company’s stock, valued at approximately $2,675,817.99. The trade was a 1.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 14.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on DYN. Lifesci Capital upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Tuesday. Sanford C. Bernstein began coverage on Dyne Therapeutics in a research report on Tuesday, June 24th. They issued a “market perform” rating and a $13.00 price objective on the stock. Jones Trading began coverage on Dyne Therapeutics in a research report on Thursday, June 26th. They issued a “buy” rating and a $30.00 price objective on the stock. Royal Bank Of Canada lowered their price objective on Dyne Therapeutics from $25.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 29th. Finally, Oppenheimer restated a “market perform” rating and issued a $13.00 price objective on shares of Dyne Therapeutics in a research report on Friday, October 10th. Four investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.07.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.